Compare F5 Inc (FFIV) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Tenet Healthcare Corporation — how do they compare? F5 Inc trades at $460.99 (market cap $26.14B), while Tenet Healthcare Corporation trades at $260 (market cap $20.98B). The key difference: F5 Inc is the larger of the two by market cap, and F5 Inc is trading nearer its 52-week high, Tenet Healthcare Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Tenet Healthcare Corporation for 15 Days on average.
| FFIV | THC | |
|---|---|---|
Market Cap | $26.14B | $20.98B |
Volume | 503,146 | 428,008 |
Sector | Technology | Health |
52-Week High | $469.79 | $280.77 |
52-Week Low | $223.99 | $161.37 |
Typical Hold Time | 38 Days | 15 Days |
Enterprise Value | $24.78B | $32.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $466.65, down 0.67% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings. The company demonstrates robust fundamentals with revenue growth from $2.7B in 2022 to $3.1B in 2025 and expanding net margins reaching 22.42%. Recent recognition as a leader in IDC MarketScape for WAAP platforms and AI security innovations highlight competitive positioning.
FFIV presents a mixed outlook with strong earnings beats and profitability offset by premium valuations (P/E 36.78). Analyst consensus leans cautious with 41% buy ratings and $416.60 price target below current levels. Key risks include competitive pressures in application security and potential valuation compression if growth moderates.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
